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1. INTRODUCTION 
 
Ischemia reperfusion injury (IRI) is an Antigen (Ag)-independent inflammatory event that 
affects several clinical settings, including surgical procedures such as liver resection and liver 
transplantation. IRI is still a major concern in the transplantation setting, causing up to 10% of 
early graft failure and leading to a higher incidence of acute and chronic rejection1. IRI is 
initiated by Kuppfer cells and hepatocytes through a massive production of reactive oxygen 
species (ROS) during the ischemic phase and, in a major degree, during the post-reperfusion 
phase. ROS directly damage hepatocytes and endothelial cells and promote the recruiment of 
neutrophils and T-cells, starting an inflammatory cascade that triggers apoptosis and necrosis. 
Clearly, there is a widespread interest regarding possible means to reduce the possibility of 
this event.  
Human liver stem cells (HLSC) are human hepatocyte progenitors cells expressing both 
markers of stem cells and hepatocytes. HLSC have been isolated in 2006 at the University of 
Turin by culturing human hepatocytes in stringent culture conditions. Adult human liver 
stem-like cells (HLSC) may be useful in regenerative medicine because they are easily 
expandable and have multiple differentiating capabilities2,3. They express several 
mesenchymal (CD29, CD73, CD44, CD90) and embryonic markers (Nanog, Sox2, Musashi1, 
Oct 3/4, Pax2), but not haematopoietic ones. Moreover, HLSC express albumin, alpha-
fetoprotein and cytokeratin 18, supporting their partial hepatic commitment2. We showed that 
HLSC could restore hepatic function and improve survival in a model of fulminant liver 
failure in immunodeficient mice3 and could generate hepatic-like tissue when seeded in liver 
acellular scaffolds4.  
Stem cell-derived extracellular vesicles (EV) are a heterogeneous population of cell-secreted 
vesicles which play a pivotal role in cell-to-cell communication; they carry specific subsets of 
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mRNA and miRNA that regulate target cells behaviour5,6. Many in vitro and in vivo studies 
demonstrated the EV therapeutic potential, showing that their beneficial effect is comparable 
to that of the stem cells they derive from7,8,9,10,11. 
 
 
2. ISOLATION, CHARACTERIZATION AND CULTURE OF HLSC 
 
HLSC were isolated from human cryopreserved hepatocytes obtained from Lonza Bioscience 
(Basel, Switzerland) and characterized2,3. HLSC were cultured in a medium containing a 3:1 
proportion of α-minimum essential medium and endothelial cell basal medium-1, 
supplemented with L-glutamine 2 mM, penicillin 100 U/mL, streptomycin 100 µg/mL and 
10% foetal calf serum (α-MEM/EBM/FCS), and maintained in a humidified 5% CO2 
incubator at 37°C. HLSC at passages 5 to 8 and 80% confluence were used in all experiments.  
 
 
3. ISOLATION OF DIL-LABELLED HLSC-EV 
 
The HLSC were previously labelled with the DIL Stain (1,1'-Dioctadecyl-3,3,3',3'- 
Tetramethylindocarbocyanine Perchlorate 'DiI'; DiIC18(3)) (Molecular Probes Life 
Technology, New York, NY, USA)11 and cultured. Once at 80% confluence, cells were 
starved overnight in RPMI/P-S medium deprived of FCS at 37°C in a humidified incubator 
with 5% CO2. Supernatants were collected, centrifuged at 3,500 rpm for 15 minutes to 
remove cell debris, and submitted to ultracentrifugation at 100,000 g for 2 hours at 4°C 
(Beckman Coulter Optima L-90 K, Fullerton, CA, USA). EV were collected and used fresh or 
stored at −80°C after re-suspension in RPMI plus 1% dimethyl sulfoxide. No difference in 
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biological activity was observed between fresh and stored EV (data not shown). 
Quantification and size distribution of EV were performed using NanoSight LM10 
(NanoSight Ltd, Minton Park, UK)9.    
 
 
4. FIRST PROJECT 
“Extracellular vesicles from human liver stem cells reduce injury in an ex 
vivo normothermic hypoxic rat liver perfusion model” 
 
Liver transplantation (LT) is currently the only successful therapy for end-stage liver disease. 
Yet, the discrepancy between organs and candidates remains its strongest limit. Several new 
strategies are under investigation for their potential to ameliorate the transplant process and 
expand the donor pool12. 
Static cold storage (SCS) is the gold standard for organ preservation. The rapid cooling of the 
liver by icy fluids together with the protective effect of specific solutions, slows 
hepatocellular metabolism and reduces ATP depletion and loss of cellular integrity13. 
Unfortunately, SCS is imperfect in preserving organs from extended criteria donors14. 
Normothermic Machine Perfusion (NMP) is an innovative alternative to SCS. Through an 
extracorporeal perfusion circuit, it keeps the organ at physiological temperature while 
providing oxygen and nutrients continuously15. At variance with SCS, NMP allows real-time 
monitoring of biomarkers and hemodynamic parameters that correlate with organ viability, 
making the transplant process more objective. Animal studies demonstrated the superiority of 
NMP compared to SCS16,17,18,19,20,21 and a Phase I study established safety and feasibility of 
this technique in humans22. Furthermore, NMP gives the unique opportunity to treat the liver 
with pharmacological interventions in the pre-transplant phase23. 
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In this study, we set up a short-duration model of ex vivo isolated rat liver NMP in which 
oxygen delivery was kept suboptimal through a low haemoglobin content in the perfusate. In 
this model, we investigated whether adding HLSC-derived EV (HLSC-EV) to the circuit 
could result in: 
i) their rapid uptake by the liver, 
ii) an appreciable reduction of the hypoxic tissue injury. 
 
 
4.1 Animals 
 
Animal studies were approved by the Ethic Committee of Istituto Superiore di Sanità 
(N.1164/2015-PR) and conducted in accordance with the National Institute of Health Guide 
for Care and Use of Laboratory Animals. Male Wistar rats aged 8-12 weeks (200-250 g 
weight) obtained from Charles Rivers (Italy) were maintained on standard conditions and 
provided with food and water ad libitum. 
 
 
4.2 Isolation of Rat Livers 
 
Animals were anesthetized through an intramuscular injection of Zolazepam (0.2 mg/Kg) and 
Xilazyne (16 mg/Kg). After intraperitoneal heparin (1,250 U) administration, a midline 
laparotomy was performed. The bowel was retracted to expose the liver, with particular 
attention to portal vein (PV), hepatic artery (HA),  inferior vena cava (IVC) and common bile 
duct (CBD)(Figure 1A-B). The CBD was cannulated with a 22G cannula, the HA was ligated 
and the PV cannulated with an 18G cannula (Figure 1C-F). After sternotomy, an incision was 
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made in the right heart ventricle to exsanguinate the animal. The liver was flushed with 40 
mL of cold Celsior solution (IGL, France) through the PV (Figure 1G-I). After perfusion, the 
liver was freed from its ligaments and the suprahepatic IVC, the infrahepatic IVC, the CBD 
and the PV were transected allowing organ removal. The isolated liver was weighed, placed 
into a Petri dish filled with ice-cold Celsior solution and transported to the perfusion room.  
 
 
Figure 1. Surgical procedure. (A) median laparotomy; (B) exposure of the liver pedicle; (C-
D) cannulation of the CBD; (E-F) cannulation of the PV; (G-H-I) flushing with cold Celsior 
solution through the PV. 
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4.3 Normothermic Machine Perfusion 
 
The NMP circuit was composed of a perfusion chamber (Figure 2A), a peristaltic pump 
(Figure 2B), an oxygenator (Hollow Fiber Oxygenator D150, Hugo Sachs Elektronik) (Figure 
2C) and a bubble trap (Figure 2D). A Transducer Amplifier Module (TAM-D) and a Servo 
Controller (SCP Type 704) (Harvard Apparatus, Hugo Sachs Elektronik) allowed constant 
pressure perfusion (8-10 mmHg) and continuous monitoring of perfusate flow (1.1-1.3 
mL/min/g liver). The perfusion chamber was linked to a warming circuit made of a 
thermocirculator (Lauda) with temperature set at 37°C (Figure 2E). 
The perfusion solution consisted of phenol red-free Williams E Medium, supplemented with 
11.6 mM glucose, 50 U/mL penicillin, 50 µg/mL streptomycin, 5 mM L-glutamine (all from 
Sigma), 1 U/ml insulin (Lilly, Italy), 1 U/mL heparin (PharmaTex, Italy), named complete 
Williams Medium. An isovolemic hemodilution was performed by adding 20 mL of fresh rat 
blood to 50 mL of complete Williams Medium, thus obtaining a mean hematocrit of 9.67 ± 
0.66%. This low haemoglobin content (roughly half of what is usually employed in similar 
perfusion settings)20 was devised to provide suboptimal oxygen delivery and induce a limited 
but progressive hypoxic injury24. The perfusion solution was gassed with 99% oxygen, and 2 
mEq/2 mL of bicarbonate were used to prevent pH fluctuations.  
Livers were flushed with complete Williams Medium and connected to the NMP circuit, 
allowing continuous perfusion at 37°C through the PV cannula for four hours in controlled 
conditions of flux and pressure. Heparin (500 U) was added hourly during perfusion. A tube 
was inserted into the CBD cannula to collect bile (Figure 3).  
Rat livers undergoing NMP were divided in two groups: NMP alone (NMP group, n=10) and 
NMP enriched with HLSC-EV (NMP+HLSC-EV group, n=9). In the NMP+HLSC-EV group, 
	 10	
EV were added to the circuit after 15 minutes from perfusion start, in a single dose of 5x108 
HLSC-EV/g of liver10. 
 
Figure 2. Normothermic Machine Perfusion. A: perfusion chamber; B: peristaltic pump; C: 
oxygenator; D: bubble trap; E: thermocirculator. 
 
 
Figure 3. Our Normothermic Machine Perfusion. 
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4.4 Perfusate Analysis 
 
Blood gas analysis (ABL 705L Radiometer, Copenhagen) was performed hourly during 
perfusion in inflow and outflow perfusate samples, testing pO2, pCO2 and pH. In addition, 
outflow samples (1 mL) were collected every 60 minutes and centrifuged at 3,500 rpm for 10 
minutes at 4°C; the cell-free supernatants were stored at -80°C until aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) 
levels were assessed by the Biochemistry Laboratory, Molinette Hospital, Turin, Italy.  
 
 
4.5 Immunofluorescence and histological analysis 
 
To analyze the HLSC-EV uptake, two liver lobes were included in Killik OCT medium (Bio-
optica) and frozen at -80°C; then serial slides were cut (3-5 µm) by a cryostat and fixed in 
acetone. After rinsing in phosphate-buffered saline (PBS), the slides were incubated with a 
blocking solution of 3% bovine serum albumin and 0.1% Tween-20 in PBS for 1 hour at 
room temperature, and then incubated overnight at 4°C with a primary antibody directed 
against rat cytochrome P450-4A (Invitrogen) at the dilution of 1:50. After washing in PBS, 
the slides were incubated with the secondary antibody Alexa Fluor 488 (Invitrogen) for 1 hour 
at room temperature. Finally, nuclei were stained with 4',6-diamidino-2-phenylindole and 
slides were mounted with Fluoromount (Sigma). Microscopy analysis was performed using a 
Cell Observer SD-ApoTome laser scanning system (Carl Zeiss).  
Two other liver lobes were formalin fixed and paraffin embedded, then sections were 
performed in the areas where the macroscopic aspect was most altered. Hematoxylin-eosin 
staining was used. The severity of histological damage was blindly scored by an experienced 
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pathologist following modified Suzuki criteria25. According to this classification, sinusoidal 
congestion, hepatocyte necrosis and ballooning degeneration are graded from 0 to 4. Each 
liver final score was determined by the summation of the grades for the three items. 
Immunohistochemistry by terminal deoxynucleotidyl transferase dUTP nick-end labelling 
(TUNEL) was performed to detect apoptosis26. Positive and negative TUNEL cells were 
blindly counted on 20 microscopic fields at 200× magnification, then the apoptosis index was 
calculated as the ratio between the number of positive cells and of total cells.  
 
 
4.6 Real-Time Quantitative RT-PCR 
 
RNA was extracted from all paraffin embedded liver samples using RecoverAll™ Total 
Nucleic Acid Isolation Kit for FFPE (Invitrogen), then quantified spectrophotometrically 
(NanoDrop 2000TM, Thermo Scientific). The subsequent analyses could be performed on 
more than half of the samples of both NMP and NMP+HLSC-EV groups. High-Capacity 
cDNA Reverse Transcription Kit (Applied BiosystemsTM) was used to synthesize cDNA from 
400 ng/µl of RNA. Then, a Real-Time PCR (Applied BiosystemsTM) was performed on 
triplicate cDNA samples according to the chemistry of Power SYBR® Green PCR Master 
Mix (Applied BiosystemsTM), using the following primers of hypoxia-induced markers:27 
a) hypoxia-inducible factor 1-alpha (HIF-1α), forward 5’-
TGTGTGTGAATTATGTTGTAAGTGGTATT-3’, reverse 5’-GTGAACAGCTGG 
GTCATTTTCAT-3’; 
b) transforming growth factor-beta 1 (TGF-β1), forward 5’- 
TTGCCCTCTACACCAACACAA-3’, reverse 5’- GGCTTGCGACCCACGTAGTA-3’. 
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The primer of the house-keeping gene actin β was forward 5’-ACCGTGAAA 
AGATGACCCAGAT-3’, reverse 5’-CACAGCCTGGATGGCTACGT-3’. Comparative 
ΔΔCt method was used to calculate the expression levels of the genes of interest normalized 
to the house-keeping gene expression. One liver explant from a healthy rat (sham) was used 
as reference sample. 
 
 
4.7 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM). Student’s t-test or analysis 
of variance with Sidak’s multi-comparison test were used where appropriate (GraphPad 
Prism, version 6.00, USA). A p value <0.05 was considered as statistically significant. 
 
 
4.8 Results 
 
After standardization, surgical procedures showed low variability between groups. Pre-
perfusion parameters in the NMP group (n=10) were similar to those in the NMP+HLSC-EV 
group (n=9), regarding liver weight, tissue temperature, warm ischemia and total ischemia 
times. All organs were able to self-regulate pH, pO2 and pCO2 during the four-hour perfusion, 
maintaining stable flow rates and venous resistances (Table 1).  
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 NMP (n=10) 
Mean (SEM) 
NMP+HLSC-EV (n=9) 
Mean (SEM) 
p value 
 Liver weight [g] 10.35 (0.41) 10.16 (0.22) 0.69 
 Pre-perfusion temperature [°C] 13.80 (1.78) 9.89 (0.89) 0.08 
 Pre-perfusion ischemia time [min]    
- Warm ischemia  3.10 (0.35) 3.56 (0.24) 0.31 
- Total ischemia  29.30 (1.51) 34.78 (2.39) 0.06 
Flow [ml/min/g liver]     
- t = 60 min 1.23 (0.06) 1.14 (0.06) 0.33 
- t = 120 min 1.30 (0.05) 1.24 (0.07) 0.49 
- t = 180 min 1.30 (0.04) 1.23 (0.07) 0.41 
- t = 240 min 1.19 (0.07) 1.21 (0.07) 0.80 
Venous resistance [mmHg/(ml/min/g liver)]    
- t = 60 min 7.22 (0.45) 8.14 (0.47) 0.18 
- t = 120 min 6.84 (0.38) 7.53 (0.47) 0.27 
- t = 180 min 6.69 (0.25) 7.52 (0.43) 0.11 
- t = 240 min 7.65 (0.59) 7.65 (0.45) 0.99 
 
pH (Inflow)    
- t = 60 min 7.52 (0.09) 7.41 (0.03) 0.35 
- t = 120 min 7.53 (0.09) 7.44 (0.02) 0.42 
- t = 180 min 7.43 (0.06) 7.48 (0.05) 0.51 
- t = 240 min 7.37 (0.08) 7.44 (0.08) 0.61 
pH (Outflow)    
- t = 60 min 7.43 (0.08) 7.39 (0.06) 0.70 
- t = 120 min 7.41 (0.09) 7.39 (0.03) 0.84 
- t = 180 min 7.33 (0.06) 7.42 (0.04) 0.24 
- t = 240 min 7.26 (0.08) 7.37 (0.05) 0.30 
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pO2 (Inflow) [mmHg]    
- t = 60 min 273 (122) 240 (102) 0.84 
- t = 120 min 343 (108) 273 (105) 0.66 
- t = 180 min 241 (71) 290 (106) 0.75 
- t = 240 min 230 (61) 239 (81) 0.93 
pO2 (Outflow) [mmHg]    
- t = 60 min 26.38 (3.67) 29.93 (3.99) 0.57 
- t = 120 min 33.05 (5.06) 42.87 (7.15) 0.37 
- t = 180 min 33.18 (4.78) 42.07 (6.51) 0.37 
- t = 240 min 25.28 (7.40) 35.69 (4.16) 0.21 
pCO2 (Inflow) [mmHg]    
- t = 60 min 39.98 (7.67) 36.83 (4.32) 0.71 
- t = 120 min 31.30 (5.34) 29.13 (3.01) 0.71 
- t = 180 min 37.53 (4.86) 29.20 (1.13) 0.10 
- t = 240 min 34.03 (4.40) 27.35 (3.78) 0.29 
pCO2 (Outflow) [mmHg]    
- t = 60 min 49.43 (9.12) 44.63 (4.24) 0.60 
- t = 120 min 38.98 (7.96) 36.10 (2.63) 0.68 
- t = 180 min 46.03 (8.46) 34.83 (1.78) 0.11 
- t = 240 min 47.60 (7.17) 34.88 (3.39) 0.11 
Table 1. Procedure’s parameters 
 
Immunofluorescence analysis (Figure 4) revealed the presence of DIL-stained HLSC-EV in 
treated livers by the end of the experiment (Figure 4C). The co-localization of HLSC-EV with 
the hepatocyte marker cytochrome P450-4A demonstrated their internalization within 
hepatocytes (Figure 4D). Histological analysis evidenced overt damage in the NMP livers, 
characterized by areas of necrosis and apoptosis, which were reduced in the NMP+HLSC-EV 
livers (Figure 4E, 4G). Tissue injury quantification by the Suzuki score (Figure 4F) showed a 
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significant decrease in the NMP+HLSC-EV livers (3.9±0.4) compared with the NMP ones 
(5.7±0.6) (p=0.030). In particular, livers treated with HLSC-EV displayed a reduced 
extension of necrotic areas, which never exceeded the mild degree (Figure 5). Also apoptosis 
was found to be significantly reduced in the NMP+HLSC-EV group (apoptosis index: 
0.06±0.01 vs. 0.14±0.03, p=0.049) (Figure 4H). 
 
Figure 4. Immunofluorescence analysis. 
 
	 17	
 
Figure 5. Suzuki Score’s parameters for tissue injury. 
 
During perfusion, biochemical analyses showed a significant gradual increase in AST, ALT 
and LDH levels in both NMP and NMP+HLSC-EV perfusate samples. AST, ALT and LDH 
reached much higher values at 4 hours than at 1 hour in each group (p<0.0001) (Figure 6). 
When compared to controls, livers treated with HLSC-EV released significantly less AST and 
LDH at 3 hours (AST: 92±14 vs. 47±7 U/L/g, p=0.018; LDH: 619±104 vs. 340±47 U/L/g, 
p=0.032) (Figure 6A, 6B) and less AST at 4 hours (134±20 vs. 80±14 U/L/g, p=0.003) 
(Figure 6A), whereas no differences were observed for ALT (Figure 6C). 
Small amounts of bile were consistently produced during the ex vivo perfusion without 
differences between groups (Figure 6D). 
The quantitative RT-PCR analysis showed that: 
a) RNA expression of HIF-1α and TGF-β1 was increased in the NMP group, if compared to 
the sham reference sample (Figure 7A, 7B); 
b) HLSC-EV treatment significantly reduced both HIF-1α and TGF-β1 RNA expression 
levels when compared to the NMP group (p<0.0001 and p=0.014, respectively) (Figure 7A, 
7B). 
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Figure 6. Biochemical analyses on perfusate and bile production. 
 
 
Figure 7. Quantitative RT-PCR analysis of HIF-1α and TGF-β1. 
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4.9 Discussion 
 
Normothermic machine perfusion is quickly gaining recognition as a liver preservation 
modality capable to improve the outcomes of extended criteria grafts16,17,18,19,20,21. Thanks to 
physiological temperature and active hepatic metabolism, NMP allows to pharmacologically 
treat the livers23 with the intent to ameliorate their quality prior to implantation. 
HLSC are liver-resident stem-like cells, partially committed to the hepatic lineage, which 
carry regenerative and hepatoprotective properties2,3. We already demonstrated that EV 
derived from HLSC and mesenchymal stem cells are able to mimic most of the cell effects 
(including apoptosis inhibition and mitogenic activity) by transferring proteins, mRNAs and 
micro-RNAs8,9,10. Possible mechanisms involved in EV effects on injured tissue include up-
regulation of anti-apoptotic genes (Bcl-xL, Bcl2, and BIRC8) and down-regulation of 
proapoptotic genes (Casp1, Casp8, and LTA).5,6,10 Therefore HLSC-EV may represent a 
treatment option for liver diseases, avoiding stem cells transplantation. 
Combining these two innovative approaches, in an ex vivo model of hypoxia-induced liver 
damage we found that HLSC-EV can be rapidly uptaken by the hepatocytes and can reduce 
hepatic injury, thus providing the rationale for a pharmacological intervention with HLSC-EV 
during NMP. 
For our purpose, we set up a simplified circuit for small organs. Because of the large body of 
literature on isolated rat liver perfusion,20,28,29,30 rat was chosen as the experimental animal. 
The morphological aspect of livers after four hours of NMP (alone or with HLSC-EV 
treatment) together with the maintained bile production evidenced that the experimental 
conditions allowed both survival and function of organs. Nonetheless, the pre-perfusion 
ischemic period (about 30 minutes) followed by a NMP with low hematocrit in the perfusate 
induced a limited but progressive hypoxic injury. This injury was proven by both the 
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increasing levels of cytolysis enzymes in the perfusate during perfusion and the necrotic and 
apoptotic areas which could be noted at the end of the experiments. 
Fluorescent microscopy confirmed the ability of the rat liver to uptake HLSC-EV8 and 
revealed the presence of HLSC-EV within hepatocytes at four hours. This uptake is more 
rapid than that observed with EV derived from mesenchymal stem cells, which were found 
within the injured tissue after at least five hours from their intravenous in vivo inoculation11. 
We hypothesize that the ex vivo isolated liver perfusion allows a faster and organ-specific 
distribution. To avoid modifications of hemodynamic parameters, we did not collect biopsy 
samples during perfusion; therefore, additional experiments are necessary to explore the 
precise timing of start of EV uptake within the liver during NMP. 
In both groups, cytolysis enzyme levels gradually increased to reach a peak at the fourth hour. 
This trend is more likely to be ascribed to the insufficient oxygen delivery than to an ex vivo 
ischemia/reperfusion phenomenon. During this injury, in the NMP+HLSC-EV group AST 
and LDH were found to be lower at different time points, suggesting a protective effect of 
HLSC-EV against hypoxia.  
The better histological integrity of the hepatic parenchyma in livers treated with HLSC-EV 
confirmed these findings. Moreover, HLSC-EV administered in NMP were able to reduce 
apoptosis by about 50%.  
Finally, the RNA over-expression of hypoxia-induced markers was significantly reduced by 
HLSC-EV treatment. In a study on livers perfused at 37°C with an oxygen carrier deficiency, 
HIF-1α gene and protein expression levels were increased30. In our setting, EV treatment 
significantly limited the HIF-1α dependent response to hypoxia, replicating the evidence 
reported in a rat model of acute kidney injury31. Furthermore, a cross-talk between HIF-1 and 
TGF-β1, a multifunctional cytokine involved in many cellular pathways (including 
inflammation, apoptosis and fibrosis), was recently described in hypoxic hepatocytes27. 
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All these data strongly suggest a role of HLSC-EV against hypoxic injury. Studies focusing 
on the characterization of HLSC-EV content are needed to clarify their mechanisms of 
protection. 
We acknowledge that our study did not include transplantation of the livers after hypoxic 
NMP, yet they were overtly damaged and unsuitable for LT. We aimed indeed to investigate 
whether HLSC-EV could reduce hypoxic injury, a necessary proof-of-concept before 
proceeding to other experiments on organ preservation/reconditioning in normoxic conditions.  
In conclusion, this study demonstrates that the NMP system can deliver stem cells-derived 
products to an ex vivo perfused liver, and suggests that NMP+HLSC-EV could represent an 
innovative approach to recondition organs before transplant. Further investigations on NMP 
models using HLSC-EV in other experimental conditions, including transplantation, are 
warranted. 
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5. SECOND PROJECT: 
“Treatment of hepatic Ischemia Reperfusion Injury with HLSC-EV: 
experimental model development in the mouse” 
 
Ischemia Reperfusion Injury (IRI) is a major issue in the clinical setting of liver 
transplantation and hepatic resective surgery. 
While clearly unavoidable for liver transplantation, warm ischemia and reperfusion are 
frequently induced during hepatic resection to reduce intra-operative bleeding, by temporary 
clamping of the hepatic pedicle (Pringle maneuver)32. This may favor the onset of 
post‐hepatectomy liver failure, which is nowadays recognized as the most dreadful 
complication after hepatic resection and the most frequent cause of postoperative death33,34. 
Clearly, there is a widespread interest regarding possible means to reduce this event. 
The aim of this study was to investigate the effects of systemic administration of HLSC-EV 
on tissue injury after partial clamping of the hepatic hilum (70%) in an in-vivo model of IRI, 
that was set up in mice.  
 
 
5.1 Animals 
 
Animal studies were approved by the Ethic Committee of Istituto Superiore di Sanità (N. 
62/2016-PR) and conducted in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals. Male C57BL/6 mice, aged 10-14 weeks (20-30 g 
weight) obtained from Molecular Biotechnology Center (MBC) animal facility (Turin, Italy) 
were maintained on standard conditions and provided with food and water ad libitum. 
	 23	
In respect of the maximum number of animals indicated by ministerial directives (40 mice), 
preliminary analysis were performed on a total of 35 animals organized as follows: 
• 3 Sham, 6 IRI and 5 IRI + HLSC-EV sacrificed after 6h 
• 4 Sham, 8 IRI and 9 IRI + HLSC-EV sacrificed after 24h 
Where Sham = sham operated animals; IRI = animals subjected to IRI and treated with 
placebo (phosphate-buffered saline); IRI + HLSC-EV = animals subjected to IRI and treated 
with HLSC-EV (Table 2). 
Table 2. Animals for preliminary analysis. 
 
 
5.2 Surgical Procedure 
 
We choose to set up un IRI’s model by selective clamping of the hepatic pedicle, because it 
represents an experimental standard widely considered in literature35,36,37. 
Animals were anesthetized trough an intramuscolar injection of Zolazepam (0.2 mg/Kg) and 
Xilazyne (16 mg/Kg). 
After disinfection of the skin surface, a median laparotomy of about 4 cm was performed to 
expose the abdominal viscera. With the use of a stereoscopic microscope (Figure 8) the liver 
was  exposed and isolated.  
 
 
 Sham IRI IRI+HLSC-EV 
Sacrificie at 6h 3 6 5 
Sacrificie at 24h 4 8 9 
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Figure 8. Surgical working base. 
 
After the organ mobilization, ischemia-reperfusion injury was induced by temporary (90 
minutes long) selective clamping of the hepatic portal pedicle for the median and left lateral 
lobes of the liver with an atraumatic clamp. This selective clamping allowed to induce a 
normothermic ischemic injury of about 70% of the hepatic parenchyma, avoiding a portal 
congestion that would cause haemodynamic instability and the consequent death of the animal 
(Figure 9). During ischemia time the animals were kept warm with an infrared lamp to avoid 
hypothermic crisis. 
After 90 minutes the clamp was removed and the median laparotomy was closed with a 6/0 
silk suture. 
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Figure 9. Surgical procedure. 
 
At the end of the procedure, the HLSC-EV or the placebo were immediately systemically 
infused through the mouse’s tail vein. The animal was kept under general anesthesia during 
the whole intervention and painkiller drugs (tramadol 2 mg/kg) were given at the end of the 
procedure, during awakening and anytime the animal gave signs of pain. Sham-operated 
animals were subjected to the same procedure, except for clamping and inoculation. 
In order to evaluate the integration and biological effect of HLSC-EV, the animals’ sacrifices 
were programmed at 6 hours and 24 hours from the end of the intervention. 
At the time of sacrifice the animals were reoperated under general anesthesia (intramuscolar 
injection of Zolazepam 0.2 mg/Kg and Xilazyne 16 mg/Kg). The previous median laparotomy 
was reopened, the sternum was cut with scissors and the heart apex was punctured in order to 
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take 1 ml of blood for the subsequent blood tests. At the end of the procedure the animals 
were sacrificed by cervical dislocation and liver samples were taken from both non-ischemic 
lobes and lobes subjected to IRI injury. 
 
 
5.3 Hystological and Immunohistochemistry analysis 
 
Bioptic samples from both ischemic lobes and non-ischemic lobes were taken. The tissues 
were fixed in formalin 10% and then embedded in paraffin. For each sample, haematoxylin 
and eosin (H&E) stain and Proliferating Cell Nuclear Antigen-labelling (PCNA) Antibody 
staining were performed. 
Microscopy analysis was performed using a Cell Observer SD-ApoTome laser scanning 
system (Carl Zeiss). 
Cell proliferation was evaluated by cellular cell count. For each animal, positive and negative 
PCNA cells were blindly counted on 20 microscopic fields (10 from the ischemic lobe and 10 
from the non-ischemic lobe) at 200× magnification, then the ratio between the number of 
positive cells and of total cells was calculated and considered as an indicator of cell 
proliferation. 
 
 
5.4 Biochemical analysis 
 
Blood samples were collected at the time of sacrifice and aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) levels were analyzed at the 
Biochemistry / Clinical Laboratory - Baldi and Riberi, Molinette Hospital, Turin, Italy. 
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5.5 Statistical analysis 
 
Data are expressed as mean ± standard error of the mean (SEM). Kruskal-Wallis test with 
Dunn correction for multiple comparisons were used where appropriate (GraphPad Prism, 
version 6.00, USA). A p value <0.05 was considered as statistically significant. 
 
 
5.6 Results 
 
We did not obtain the results we expected and some of them still appear to be not reliable, 
probably because of the small sample size. Citolysis markers (AST, ALT, LDH) levels did 
not show significative differences between the three populations in the 6-hours group (Figure 
10A). Even though the statistical analysis does not support our first hypotesis, we strongly 
believe that the lack of evidence regarding the EV administration protective effect is related to 
the small sample size. 
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Figure 10. Biochemical analysis. (A) ALT, AST and LDH levels at 6 hours; (B) ALT, AST 
and LDH levels at 24 hours: ALT (*p=0.046 IRI vs IRI+HLSC-EV, #p=0.0006 sham vs 
IRI+HLSC-EV), AST (*p=0.020 IRI vs IRI+HLSC-EV, #p=0.0057 sham vs IRI+HLSC-EV) 
and LDH (*p=0.028 IRI vs IRI+HLSC-EV, #p=0.0050 sham vs IRI+HLSC-EV). 
 
 
The analysis of the differences between populations in the 24 hours group demonstrated worst 
results when EV were administered (Figure 10B).  
This finding is quite unexpected since no published paper reported similar observations 
before; the citolysis marker levels in the IRI group were significantly lower than expected and 
lower than standard post IRI levels;  furthermore they showed no differences from the levels 
observed in the Sham group. Since a direct EV citolytic effect is extremely unlikely we 
believe that this finding is related to heterogeneity in the surgical procedures, most probably 
to uncomplete clamping due to the small size of the specimen. 
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On the other hand, the results concerning the HLSC-EV effects on cell proliferation appear to 
be more promising. We analized liver samples obtained at the time of sacrifice using PCNA 
Antibody staining. Figure 11 shows the results regarding the 24 hours group. 
 
Figure 11. Immunohistochemical analysis. (A) PCNA staining, 200x magnification: PCNA+ 
cells are brown; (B) Percentage of PCNA+ cells on 10 microscopic fields (IRI = ischemic 
lobe; NO-IRI = non ischemic lobe). 
#p=0.024 IRI+HLSC-EV vs sham; *p=0.044 IRI+HLSC-EV vs IRI.
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Analysis were performed first on the liver parenchima where IRI was induced by vascular 
clamping (70% of liver parenchyma). HLSC-EV administration was associated with an 
increased PCNA-positive cell rate compared to the other groups; there was a significant 
difference between the IRI+HLSC-EV and the sham group (p = 0.024) and a trend of 
significativity when IRI and IRI+HLSC-EV groups were compared (p = 0.12). Again, we 
believe this lack of significance to be related to the small sample size. 
The cell proliferation rate was also found to be significantly higher (p = 0.044) in the HLSC-
EV group compared to the IRI group when analysis were performend on NO-IRI induced 
liver parenchima (30%); this observation confirms previous literarure data regarding the EV 
regenerative effect on healthy tissues8. No difference was found between the HSLC-EV and 
the sham group; again, this could be due to the small sample size or to the presence of an 
outlier in the sham group. 
 
	
5.7 Discussion 
 
Our preliminary results led us to believe that we need to make some rearrangements to our 
work, particularly concerning the timing of sacrifice. Recently published papers report that 
the regenerative effect of EV on the liver occurs early after administration; Nong et al.38 
analysed post-IRI cells replication rate after administration of EV derived from stromal 
mesenchimal cells and observed relevant anti-apoptotic and anti-oxidative effects at 1, 3 and 6 
hours after the clamping induced vascular damage. Our previous work concerning the 
normothermic ex-vivo liver perfusion model also showed an HLSC-EV protective effect after 
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3-4 hours from the treatment, pointing out an early interaction between EV and damaged liver 
cells. 
The heterogeneous effectiveness of vascular clamping and of EV administration, mostly 
related to the small size of the mice, requires adjustments in the surgical procedures as well; 
in particular we plan to use an easier way of EV administration through the inferior vena cava 
instead of the tail vein 38. Furthermore, Haga et al.39 have recently obtained interesting results 
using an higher EV dosage; we believe that an increase in EV blood concentration could lead 
to better results. 
Given all the limitations that were mentioned above, we asked the ISS for the authorisation to 
continue our research and we recently obtained it. 
We strongly believe that these adjustments will allow us to demonstrate the effective 
interaction between products derived from human liver stem cells and murine hepatocytes in 
the presence of ischemia / reperfusion injury and to demonstrate the biological effects on 
morphology and liver function. 
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